Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolvaptan - Otsuka Pharmaceutical

Drug Profile

Tolvaptan - Otsuka Pharmaceutical

Alternative Names: Jinarc; Jynarque; OPC 61815; OPC-156; OPC-41061; Samsca; Samsca granules 1%

Latest Information Update: 01 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka America Pharmaceutical; Otsuka Pharmaceutical
  • Class Antihypertensives; Benzazepines; Heart failure therapies; Small molecules; Urologics
  • Mechanism of Action Diuretics; Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autosomal dominant polycystic kidney disease; Hyponatraemia; Polycystic kidney disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Autosomal dominant polycystic kidney disease; Cardiac oedema; Hyponatraemia; Oedema
  • Registered Ascites; Heart failure; Renal failure
  • Phase II Benign prostatic hyperplasia
  • No development reported Cystinuria; Unspecified

Most Recent Events

  • 29 Sep 2021 Biomarkers information updated
  • 21 May 2021 Phase-III clinical trials in Hyponatraemia in Australia (PO) (ACTRN12619001683123)
  • 22 Mar 2021 Launched for Cardiac oedema in Japan (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top